Full Text PDF Similar Articles Mail to Author

¹Department of Radiation Oncology, Inonu University, Faculty of Medicine, Malatya-Turkey
²Department of Medical Oncology, Inonu University, Faculty of Medicine, Malatya-Turkey
³Department of Pathology, Inonu University, Faculty of Medicine, Malatya-Turkey
⁴Department of Otolaryngology, Malatya Training and Research Hospital, Malatya-Turkey DOI : 10.5505/tjo.2017.1607 Neuroendocrine tumors of the larynx account for<1% of all laryngeal cancers. Laryngeal small cell carcinomas of the neuroendocrine type (SCNC) account for <0.5% of all laryngeal tumors. We report two cases of 65- and 75-year old men with small cell carcinoma of the supraglottic larynx. The patients were treated with induction chemotherapy (cisplatin-etoposide) and chemoradiotherapy (cisplatin-etoposide). The first patient was alive until 26 months from diagnosis. However, multiple brain metastases developed in the second patient, and he died 16 months after diagnosis. Small cell neuroendocrine carcinomas are very aggressive neoplasms. A combination of platinum-based chemotherapy and radiotherapy is the mainstay of the treatment for SCNC, which is considered to be a systemic disease. Keywords : Larynx; radiotherapy; small cell